Stevanato Group S.p.A. $STVN Shares Sold by Roubaix Capital LLC

Roubaix Capital LLC decreased its position in Stevanato Group S.p.A. (NYSE:STVN – Free Report) by 17.1% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 328,858 shares of the company’s stock after selling 67,964 shares during the quarter. Stevanato Group accounts for approximately 2.7% of Roubaix Capital LLC’s portfolio, making the stock its 6th largest position. Roubaix Capital LLC owned about 0.11% of Stevanato Group worth $6,899,000 at the end of the most recent reporting period.

A number of other large investors also recently added to or reduced their stakes in the company. Fifth Third Bancorp boosted its position in shares of Stevanato Group by 22.6% during the first quarter. Fifth Third Bancorp now owns 4,196 shares of the company’s stock worth $58,000 after buying an additional 773 shares during the period. Integrated Wealth Concepts LLC purchased a new stake in shares of Stevanato Group in the 2nd quarter valued at $59,000. State of Wyoming purchased a new stake in shares of Stevanato Group in the 3rd quarter valued at $75,000. First Bank & Trust lifted its stake in Stevanato Group by 3.4% during the 2nd quarter. First Bank & Trust now owns 18,417 shares of the company’s stock worth $333,000 after acquiring an additional 603 shares in the last quarter. Finally, Glenmede Trust Co. NA lifted its stake in Stevanato Group by 29.5% during the 1st quarter. Glenmede Trust Co. NA now owns 38,461 shares of the company’s stock worth $529,000 after acquiring an additional 8,770 shares in the last quarter.

Stevanato Group Stock Up 0.8%

Stevanato Group stock opened at €15.37 on Wednesday. Stevanato Group S.p.A. has a twelve month low of €12.05 and a twelve month high of €24.01. The stock’s fifty day simple moving average is €18.94 and its 200-day simple moving average is €17.91. The company has a current ratio of 1.73, a quick ratio of 1.19 and a debt-to-equity ratio of 0.22. The firm has a market capitalization of $4.65 billion, a P/E ratio of 26.49, a P/E/G ratio of 1.60 and a beta of 0.80.

Stevanato Group (NYSE:STVN – Get Free Report) last announced its quarterly earnings data on Tuesday, November 3rd. The company reported €0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of €0.17 by (€0.01). The company had revenue of €326.06 million during the quarter. Stevanato Group had a net margin of 11.24% and a return on equity of 10.51%. As a group, equities analysts expect that Stevanato Group S.p.A. will post 0.67 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director William J. Federici purchased 20,000 shares of Stevanato Group stock in a transaction on Monday, November 9th. The shares were bought at an average price of €13.72 per share, with a total value of €274,400.00. Following the transaction, the director directly owned 46,991 shares of the company’s stock, valued at approximately €644,716.52. This trade represents a 74.10% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Donald E. Morel, Jr. acquired 25,000 shares of the firm’s stock in a transaction dated Friday, November 6th. The stock was bought at an average price of €13.07 per share, with a total value of €326,750.00. Following the purchase, the director directly owned 62,424 shares in the company, valued at approximately €815,881.68. This trade represents a 66.80% increase in their position. The disclosure for this purchase is available in the SEC filing.

Wall Street Analyst Weigh In

STVN has been the subject of a number of research analyst reports. Deutsche Bank began coverage on Stevanato Group in a report on Wednesday, October 7th. They set a “hold” rating for the company. Citigroup cut their price target on shares of Stevanato Group from $26.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, November 4th. Weiss Ratings upgraded shares of Stevanato Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Thursday, August 27th. William Blair cut shares of Stevanato Group from an “outperform” rating to a “market perform” rating in a research report on Wednesday, November 4th. Finally, UBS Group lowered their price objective on shares of Stevanato Group from $23.00 to $16.00 and set a “neutral” rating for the company in a research note on Wednesday, November 4th. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy”.

Read Our Latest Analysis on STVN

About Stevanato Group

(Free Report)

Stevanato Group is an Italian provider of drug-containment and drug-delivery solutions for the pharmaceutical, biotechnology and diagnostic industries. Founded in 1949 by Giovanni Stevanato, the company began as a glassmaking business and has expanded into a global supplier of products and services for the life sciences sector. The company makes primary packaging for injectable medicines, including glass vials, cartridges, syringes and ampoules. Its offerings also include ready-to-use containers, as well as services such as product development, analytical testing and packaging support.

Read More

Institutional Ownership by Quarter for Stevanato Group (NYSE:STVN)

Receive News & Ratings for Stevanato Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stevanato Group and related companies with MarketBeat.com's FREE daily email newsletter.